Defactinib companion diagnostic - Verastem/LabCorp

Drug Profile

Defactinib companion diagnostic - Verastem/LabCorp

Alternative Names: Defactinib companion diagnostic; VS-6063 companion diagnostic

Latest Information Update: 17 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratory Corporation of America Holdings; Verastem
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Mesothelioma

Most Recent Events

  • 10 Jan 2013 Verastem and Laboratory Corporation of America Holding are collaborating to develop a companion diagnostic for defactinib
  • 09 Jan 2013 Clinical trials in Mesothelioma (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top